Inlyta (Axitinib) Patent Expiration, LOE Window & CMS Spending
Inlyta (Axitinib) by Pfizer: FDA Orange Book core substance LOE 2031-06-14 (last listed 2037-07-12), 1 AB generics, $489.5M 2024 CMS Part D & Medicaid spend, and 8 CA HCAI SB 17 wholesale price filings.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Pfizer |
| FDA Application & Pathway | N202324 (NDA) |
| Exclusivity / Cliff Horizon | Long-Dated Protection (2036+) |
| Core Active-Ingredient LOE Date | 2031-06-14 |
| Last Listed Patent or Exclusivity Date | 2037-07-12 |
| Orange Book Patents (*PED Extensions) | 8 patents (4 *PED) |
| Active AB-Rated Generic Competitors | 1 |
| 2024 CMS Total Public Spend | $489.5M |
| 2024 Medicare Part D Spend | $438.9M |
| 2024 Medicaid Spend | $50.6M |
| Reported Wholesale Price Change (CA SB 17) | 8 WAC filings (max 26.0% 2-yr change) |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for Pfizer across sibling Meru public-data platforms.